SIMVICITY

Serial Number 90321970
734

Registration Progress

Application Filed
Nov 16, 2020
Under Examination
Feb 15, 2022
Approved for Publication
Dec 21, 2021
Published for Opposition
Dec 21, 2021
Registered

Basic Information

Serial Number
90321970
Filing Date
November 16, 2020
Published for Opposition
December 21, 2021
Drawing Code
4

Status Summary

Current Status
Active
Status Code
734
Status Date
Aug 1, 2024
Application
Pending
Classes
005

Rights Holder

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED

24
Address
BUILDING 730 KENT SCIENCE PARK
SITTINGBOURNE, KENT ME9 8AG
GB

Ownership History

GW Research Limited

Original Applicant
99
Cambridge GB

GW Research Limited

Owner at Publication
99
Cambridge GB

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED

New Owner After Publication #1
24
SITTINGBOURNE, KENT GB

Legal Representation

Attorney
Michael T. Olsen

USPTO Deadlines

All Deadlines Cleared

All 4 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

43 events
Date Code Type Description
Feb 24, 2025 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 1, 2024 EXT5 S SOU EXTENSION 5 FILED
Aug 1, 2024 EX5G S SOU EXTENSION 5 GRANTED
Aug 1, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 1, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
Jan 20, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 18, 2024 EX4G S SOU EXTENSION 4 GRANTED
Jan 18, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
Jan 18, 2024 EXT4 S SOU EXTENSION 4 FILED
Jul 15, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 13, 2023 EX3G S SOU EXTENSION 3 GRANTED
Jul 13, 2023 EXT3 S SOU EXTENSION 3 FILED
Jul 13, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
Feb 17, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 15, 2023 EX2G S SOU EXTENSION 2 GRANTED
Feb 15, 2023 EXT2 S SOU EXTENSION 2 FILED
Feb 15, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
Aug 10, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 8, 2022 EX1G S SOU EXTENSION 1 GRANTED
Aug 8, 2022 EXT1 S SOU EXTENSION 1 FILED
Aug 8, 2022 EEXT I SOU TEAS EXTENSION RECEIVED
Feb 15, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 21, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 21, 2021 PUBO A PUBLISHED FOR OPPOSITION
Dec 1, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 15, 2021 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 14, 2021 CNEA R EXAMINERS AMENDMENT -WRITTEN
Nov 14, 2021 XAEC I EXAMINER'S AMENDMENT ENTERED
Nov 14, 2021 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 14, 2021 GNEA O EXAMINERS AMENDMENT E-MAILED
Nov 3, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 3, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 3, 2021 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 15, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 15, 2021 ECDR I TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Sep 15, 2021 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 15, 2021 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 3, 2021 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 3, 2021 GNRT F NON-FINAL ACTION E-MAILED
May 3, 2021 CNRT R NON-FINAL ACTION WRITTEN
Apr 26, 2021 DOCK D ASSIGNED TO EXAMINER
Jan 15, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 19, 2020 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical and veterinary preparations and substances for the treatment of neurological conditions, disorders, and diseases; pharmaceutical preparations and substances for the treatment of pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, cancer and cancer symptoms, perioperative pain, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, hypoxic-ischaemic encephalopathy, symptoms of neurogenic disorders, movement disorders, psychotic disorders, diseases of the central nervous system, stroke and head injuries, motion sickness and chemically induced sickness, psychiatric illnesses, post-traumatic stress disorder, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with type II diabetes, bulimia, schizophrenia, chron's disease, alzheimer's disease, bone disorders, inflammatory disorders, sleep and sleep disorders, and drug, alcohol, and nicotine abuse; Pharmaceutical preparations and substances for the treatment of neurological conditions, disorders, and diseases; herbs for medicinal purposes; medicinal herbs; medicinal oils; Medicinal infusions for treating neurological conditions, disorders, and diseases; Pure extracts of medicinal plants and herbs for medical purposes; Dietetic foods adapted for medical purposes; herb teas for medicinal purposes; plant extracts for pharmaceutical purposes

Additional Information

Translation
The wording SIMVICITY has no meaning in a foreign language.

Classification

International Classes
005